Skip to main content

Published locations for Meta-analysis confirms no OS benefit from antiangiogenics for NSCLC patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Meta-analysis confirms no OS benefit from antiangiogenics for NSCLC patients

User login

  • Reset your password
  • /content/meta-analysis-confirms-no-os-benefit-antiangiogenics-nsclc-patients
  • /familypracticenews/article/102952/lung-cancer/meta-analysis-confirms-no-os-benefit-antiangiogenics
  • /internalmedicinenews/article/102952/lung-cancer/meta-analysis-confirms-no-os-benefit-antiangiogenics
  • /oncologypractice/article/102952/lung-cancer/meta-analysis-confirms-no-os-benefit-antiangiogenics
  • /hematology-oncology/article/102952/lung-cancer/meta-analysis-confirms-no-os-benefit-antiangiogenics
  • /internalmedicine/article/102952/lung-cancer/meta-analysis-confirms-no-os-benefit-antiangiogenics
  • /familymedicine/article/102952/lung-cancer/meta-analysis-confirms-no-os-benefit-antiangiogenics-nsclc
  • /chestphysician/article/102952/lung-cancer/meta-analysis-confirms-no-os-benefit-antiangiogenics-nsclc